Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med (2016) 0.87

Lack of association between chronic exposure to biomass fuel smoke and markers of right ventricular pressure overload at high altitude. Am Heart J (2014) 0.80

Elevated pulmonary artery pressure and brain natriuretic peptide in high altitude pulmonary edema susceptible non-mountaineers. Sci Rep (2016) 0.78

Preliminary Development of a DNA Aptamer-Magnetic Bead Capture Electrochemiluminescence Sandwich Assay for Brain Natriuretic Peptide. Microchem J (2014) 0.77

Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment. Anat Cell Biol (2016) 0.76

Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulm Med (2017) 0.75

Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.75

The usefulness of brain natriuretic peptide level in diagnosis and prognosis of patients admitted to critical care unit with shortness of breath. J Emerg Trauma Shock (2015) 0.75

Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice. Basic Res Cardiol (2016) 0.75

NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy. Iran J Pediatr (2016) 0.75

Non-invasive evaluation of hemodynamics in pulmonary hypertension by a Septal angle measured by computed tomography pulmonary angiography: Comparison with right-heart catheterization and association with N-terminal pro-B-type natriuretic peptide. Exp Ther Med (2013) 0.75

Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Blood (2017) 0.75

Diagnostic Approach to Pulmonary Hypertension in Premature Neonates. Children (Basel) (2017) 0.75

New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. Int J Physiol Pathophysiol Pharmacol (2017) 0.75

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21

Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev (1995) 5.45

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med (2000) 5.34

Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation (2001) 4.38

A new natriuretic peptide in porcine brain. Nature (1988) 4.22

Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell (1999) 4.19

Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev (2000) 4.10

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07

Natriuretic peptides. J Am Coll Cardiol (2007) 3.91

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev (2005) 3.80

Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 3.48

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 3.37

The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res (2004) 3.37

A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (1989) 3.21

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20

Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12

Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med (1951) 3.00

Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A (1997) 2.99

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84

Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation (2000) 2.78

Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76

Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A (2000) 2.58

Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol (1998) 2.52

Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49

Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 2.43

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest (2003) 2.37

Pathology of pulmonary hypertension. Clin Chest Med (2007) 2.34

Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet (1993) 2.30

A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol (1993) 2.26

Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest (1995) 2.22

Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med (2005) 2.19

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16

A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol (1994) 2.15

Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest (1995) 2.15

Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol (2000) 2.14

Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol (2002) 2.13

Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07

The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell (1989) 2.07

Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology (1992) 2.06

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest (2001) 2.03

Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell (1986) 1.98

Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol (2006) 1.98

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res (2004) 1.95

Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation (2003) 1.92

Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res (2000) 1.88

Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 1.87

N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation (2005) 1.86

Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol (2007) 1.85

Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res (2003) 1.82

Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol (2003) 1.78

Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest (2006) 1.75

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72

Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J (2005) 1.72

Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest (2005) 1.70

Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol (2001) 1.69

Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J (1995) 1.68

Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61

Molecular biology of the natriuretic peptides and their receptors. Circulation (1992) 1.60

Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest (1994) 1.60

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol (2004) 1.58

Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation (1996) 1.55

Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther (2004) 1.54

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol (1989) 1.52

Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation (2009) 1.50

Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+. Circ Res (1998) 1.50

Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab (2001) 1.47

Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) (2001) 1.44

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol (2003) 1.43

Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal (2001) 1.43

Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest (1996) 1.43

Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation (1995) 1.41

Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem (1997) 1.37

Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens (1992) 1.35

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35

A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem (1992) 1.34

Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation (2003) 1.32

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol (1999) 1.30

Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther (1997) 1.29

Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension (1995) 1.29

The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 1.27

Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation (2005) 1.27

Pulmonary hypertension and inflammation. J Lab Clin Med (1998) 1.25

Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail (2004) 1.24

Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem (1991) 1.24

Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol (1996) 1.23

Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) (1995) 1.23

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23

Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res (1991) 1.23

Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol (2007) 1.23

Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab (1993) 1.21

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J (2002) 1.21

Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun (1989) 1.21

B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19

Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest (2005) 1.19

Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett (1990) 1.16

Regulation of rat brain natriuretic peptide transcription. A potential role for GATA-related transcription factors in myocardial cell gene expression. J Biol Chem (1994) 1.15

Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med (2005) 1.75

Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J (2013) 1.61

Successful determination of lower inflection point and maximal compliance in a population of patients with acute respiratory distress syndrome. Crit Care Med (2002) 1.60

Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice. Cardiovasc Res (2013) 1.60

The right ventricle in sepsis. Clin Chest Med (2008) 1.03

Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest (2006) 1.02

Genetic disruption of protein kinase Cδ reduces endotoxin-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2012) 0.95

Pulmonary arterial hypertension: new insights and new hope. Respirology (2006) 0.94

Partial anomalous pulmonary venous return presenting with adult-onset pulmonary hypertension. Pulm Circ (2012) 0.93

Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. Chest (2002) 0.92

Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle. Crit Care Med (2007) 0.91

Pulmonary hypertension in a stable community-based COPD population. Lung (2011) 0.87

Diagnosis and management of pulmonary arterial hypertension. Pulm Med (2011) 0.87

The case for increased funding for research in pulmonary and critical care. Am J Respir Crit Care Med (2012) 0.86

Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol (2005) 0.86

Management of acute right ventricular failure in the intensive care unit. Ann Am Thorac Soc (2014) 0.86

Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension. Stem Cells Dev (2009) 0.85

Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. J Heart Lung Transplant (2011) 0.85

Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) (2004) 0.85

Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung (2011) 0.84

Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis (2011) 0.83

Hemodynamic monitoring in sepsis. Crit Care Clin (2009) 0.82

Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emerg Med Australas (2013) 0.82

Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.79

C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade. Life Sci (2011) 0.79

Impact of endotracheal tube size on preextubation respiratory variables. J Crit Care (2010) 0.79

Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism. J Thromb Thrombolysis (2015) 0.79

WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Prog Cardiovasc Dis (2012) 0.78

Cardiac atria are the primary source of ANP release in hypoxia-adapted rats. Life Sci (2010) 0.77

Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med (2013) 0.76

Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Ann Am Thorac Soc (2014) 0.75

NO: more than just a vasodilator in lung transplantation. Am J Respir Cell Mol Biol (2002) 0.75

Initial risk assessment for pulmonary hypertension in patients with COPD. Lung (2011) 0.75

Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Blood Coagul Fibrinolysis (2017) 0.75

Pulmonary puzzle. An unusual cause of chest pain. Diagnosis: Cor triatriatum sinistrum with secondary unilateral pulmonary venous hypertension and right lung hypoplasia. Thorax (2011) 0.75